Rheumatoid arthritis: vizsgálatok itt: Németország
45 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleA Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA)
- Where
- Erlangen, Heidelberg
- Életkor
- 18 év and over
- People
- 56 worldwide
- Run by
- Cullinan Therapeutics Inc.
See details and how to join2024-519114-31-00 · EU 2024-519114-31-00 - 1/2. fázisTaking peopleA Study of AZD0120 in Autoimmune Diseases
- Where
- Berlin, Erlangen, Hamburg, Jena, Mainz, Würzburg
- Életkor
- 18 év to 75 év
- People
- 27 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07295847 - 1/2. fázisTaking peopleReduction of plasma cells as an approach to reset autoimmunity in rheumatoid arthritis
- Where
- Berlin, Erlangen
- Életkor
- 18 év and over
- People
- 23
- Run by
- Charite Universitaetsmedizin Berlin KöR
See details and how to join2024-511536-27-00 · EU 2024-511536-27-00 - 1. fázisTaking peopleStudy Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
- Where
- Bonn, Jena, Mainz, Muenster, Munich
- Életkor
- 18 év to 65 év
- People
- 48 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07201558 · EU 2025-522273-10-00 - 1/2. fázisTaking peopleA Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
- Where
- Berlin, Cologne, Herne, Munich, Sendenhorst
- Életkor
- 18 év to 65 év
- People
- 84 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07412704 · EU 2025-520666-22-00 - 1. fázisTaking peopleA Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis
- Where
- Berlin
- Életkor
- 18 év to 70 év
- People
- 36 worldwide
- Run by
- Jade Biosciences, Inc.
See details and how to joinNCT07533955 - 1. fázisTaking peopleA Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
- Where
- Erlangen, Heidelberg
- Életkor
- 18 év and over
- People
- 37 worldwide
- Run by
- Cullinan Therapeutics Inc.
See details and how to joinNCT06994143 - 1. fázisTaking peopleA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Where
- Cologne, Erlangen, Magdeburg
- Életkor
- 18 év to 70 év
- People
- 72 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00 - 1/2. fázisTaking peopleControlling Hyperactive Immunity With Long-lived Lymphocytes
- Where
- Düsseldorf, Erlangen
- Életkor
- 18 év and over
- People
- 16 worldwide
- Run by
- Quell Therapeutics Limited
See details and how to joinNCT07473154 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
- Where
- Dresden, Herne
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07137598 - 2. fázisTaking peopleAn Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
- Where
- Dresden, Herne
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07620392 · EU 2025-523579-47-00 - 1/2. fázisTaking peopleStudy QEL-005-CLN-01. Phase I/II study of QEL-005 in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).
- Where
- Duesseldorf, Erlangen, Magdeburg
- Életkor
- 18 év and over
- People
- 8 worldwide
- Run by
- Quell Therapeutics Limited
See details and how to join2025-523971-46-00 · EU 2025-523971-46-00 - No phaseTaking peopleA Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
- Where
- Altenburg, Amberg, Augsburg, Bad Endenbach, Bad Pyrmont, Bamberg, Berlin, Bielefeld, Braunschweig, Chemnitz, Coburg, Daun, Dresden, Düren, Ehringshausen, Elsterwerda, Erfurt, Erlangen, Euskirchen, Frankfurt am Main, Freiberg, Freiburg im Breisgau, Gifhorn, Greifswald, Halle, Hamburg, Hanover, Heidelberg, Herne, Hohen Neuendorf, Homburg, Hoppegarten, Kaiserslautern, Kassel, Kaufering, Leipzig, Ludwigslust, Magdeburg, Marktredwitz, Meerbusch, Monheim am Rhein, Munich, Naumburg, Neubrandenburg, Neunkirchen, Osnabrück, Pfarrkirchen, Planegg, Plauen, Potsdam, Püttlingen, Ratingen, Rendsburg, Schwerin, Templin, Tübingen, Ulm, Waren, Weimar, Weyhe, Wittlich, Wuppertal, Zweibrücken, Zwickau
- Életkor
- 18 év and over
- People
- 678
- Run by
- AbbVie
See details and how to joinNCT06712628 - 1. fázisNot yet taking people in NémetországA Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
- Where
- Berlin, Erlangen, Magdeburg, Würzburg
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07873931 - 2. fázisTaking peopleA Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
- Where
- Bad Doberan, Berlin, Hamburg, Sendenhorst
- Életkor
- 18 év and over
- People
- 320 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07276581 - 2. fázisTaking peopleA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
- Where
- Bonn, Cologne, Frankfurt Am Main, Hamburg, Jena, Wetzlar
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- AbbVie
See details and how to joinNCT06972446 · EU 2025-520721-21-00 - 2. fázisTaking peopleA study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflammation in adult participants with moderately to severely active rheumatoid arthritis.
- Where
- Berlin, Hamburg, Sendenhorst
- Életkor
- 18 év and over
- People
- 97 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-522076-85-00 · EU 2025-522076-85-00 - 1. fázisTaking peoplePhase 1 Single Dose Study of JADE201 in Participants with Rheumatoid Arthritis
- Where
- Berlin
- Életkor
- 18 év and over
- People
- 24 worldwide
- Run by
- Jade Biosciences Inc.
See details and how to join2025-524746-96-00 · EU 2025-524746-96-00 - 2. fázisTaking peopleA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- Where
- Cologne, Düsseldorf, Leipzig, München
- Életkor
- 18 év to 75 év
- People
- 220 worldwide
- Run by
- Amgen
See details and how to joinNCT06570798 - No phaseNot yet taking people in NémetországDETECTRA: Remote Monitoring to Detect Rheumatoid Arthritis Flares and Treatment Response
- Where
- Berlin, Bochum
- Életkor
- 18 év to 80 év
- People
- 320 worldwide
- Run by
- Centre Hospitalier Universitaire Vaudois
See details and how to joinNCT07857993 - No phaseTaking peopleExactech Shoulder Post Market Clinical Follow-up Study
- Where
- Erlangen, Münster
- Életkor
- 21 év and over
- People
- 20 000 worldwide
- Run by
- Exactech
See details and how to joinNCT05603728 - No phaseNot yet taking people in NémetországPix-Risk: Early Detection of Rheumatoid Arthritis Via the DETECTRA Platform
- Where
- Berlin, Bochum
- Életkor
- 18 év and over
- People
- 142 worldwide
- Run by
- Centre Hospitalier Universitaire Vaudois
See details and how to joinNCT07825233 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or who Cannot Tolerate TNF and/or JAK Inhibitors
- Where
- Dresden, Hamburg, Herne, Ratingen
- Életkor
- 18 év and over
- People
- 89 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2025-521034-28-00 · EU 2025-521034-28-00 - 1. fázisTaking peopleA Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sjögren's Disease (SjD)
- Where
- Berlin
- Életkor
- 18 év and over
- People
- 20
- Run by
- AbbVie Deutschland GmbH & Co. KG
See details and how to join2026-526282-25-00 · EU 2026-526282-25-00 - 1. fázisTaking peopleTreatment of patients with autoantibody-positive autoimmune diseases and severe interstitial lung fibrosis with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - a single center Phase I/II clinical trial (HD-CAR-ILD-1)
- Where
- Heidelberg
- Életkor
- 18 év and over
- People
- 10
- Run by
- Universitaetsklinikum Heidelberg AöR
See details and how to join2024-519592-26-00 · EU 2024-519592-26-00